Literature DB >> 33322125

Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition.

Josefine Graef1, Carolin Senger2, Christoph Wetz1, Alexander D J Baur1,3, Anne K Kluge2, Mathias Lukas4,5, Julian M M Rogasch1, Thula C Walter-Rittel1, David Kohnert1, Marcus Makowski5,6, Güliz Acker7,8, Kai Huang1, Volker Budach2, Holger Amthauer1, Imke Schatka1, Christian Furth1.   

Abstract

Ga-68-DOTATOC-PET/MRI can affect the planning target volume (PTV) definition of meningiomas before radiosurgery. A shorter tracer uptake time before image acquisition could allow the examination of more patients. The aim of this study was to investigate if shortening uptake time is possible without compromising diagnostic accuracy and PET volume. Fifteen patients (f = 12; mean age 52 years (34-80 years)) with meningiomas were prospectively examined with dynamic [68Ga]Ga-68-labeled [DOTA0-Phe1-Tyr3] octreotide (Ga-68-DOTATOC)-PET/MRI over 70 min before radiosurgery planning. Meningiomas were delineated manually in the PET dataset. PET volumes at each time point were compared to the reference standard 60 min post tracer injection (p.i.) using the Friedman test followed by a Wilcoxon signed-rank test and Bonferroni correction. In all patients, the earliest time point with 100% lesion detection compared to 60 min p.i. was identified. PET volumes did not change significantly from 15 min p.i. (p = 1.0) compared to 60 min p.i. The earliest time point with 100% lesion detection in all patients was 10 min p.i. In patients with meningiomas undergoing Ga-68-DOTATOC-PET, the tracer uptake time can safely be reduced to 15 min p.i. with comparable PET volume and 100% lesion detection compared to 60 min p.i.

Entities:  

Keywords:  DOTATOC; PET; meningioma; radiosurgery

Year:  2020        PMID: 33322125      PMCID: PMC7763245          DOI: 10.3390/diagnostics10121084

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  28 in total

1.  Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.

Authors:  Ali Afshar-Oromieh; Frederik L Giesel; Heinz G Linhart; Uwe Haberkorn; Sabine Haufe; Stephanie E Combs; Dino Podlesek; Michael Eisenhut; Clemens Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-05       Impact factor: 9.236

2.  PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.

Authors:  M Henze; J Schuhmacher; P Hipp; J Kowalski; D W Becker; J Doll; H R Mäcke; M Hofmann; J Debus; U Haberkorn
Journal:  J Nucl Med       Date:  2001-07       Impact factor: 10.057

3.  Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

Authors:  Katharina Seystahl; Veit Stoecklein; Ulrich Schüller; Elisabeth Rushing; Guillaume Nicolas; Niklaus Schäfer; Harun Ilhan; Athina Pangalu; Michael Weller; Jörg-Christian Tonn; Michael Sommerauer; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

4.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013.

Authors:  Quinn T Ostrom; Haley Gittleman; Jordan Xu; Courtney Kromer; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2016-10-01       Impact factor: 12.300

5.  Impact of 68Ga-DOTATOC PET/MRI on robotic radiosurgery treatment planning in meningioma patients: first experiences in a single institution.

Authors:  Güliz Acker; Anne Kluge; Mathias Lukas; Alfredo Conti; Diana Pasemann; Franziska Meinert; Phuong Thuy Anh Nguyen; Claudius Jelgersma; Franziska Loebel; Volker Budach; Peter Vajkoczy; Christian Furth; Alexander D J Baur; Carolin Senger
Journal:  Neurosurg Focus       Date:  2019-06-01       Impact factor: 4.047

Review 6.  Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.

Authors:  Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2015-01       Impact factor: 5.115

7.  [Somatostatin receptor PET/CT (SSTR-PET/CT)].

Authors:  C Boy; T Poeppel; J Kotzerke; B J Krause; H Amthauer; R P Baum; I Buchmann; S Ezziddin; D Führer; M Gabriel; T Kuwert; H Lahner; T Lauenstein; H R Maecke; J Nagarajah; F Rösch; K Scheidhauer; M Schmidt; M A Walter; A Bockisch
Journal:  Nuklearmedizin       Date:  2018-02-21       Impact factor: 1.379

8.  68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?

Authors:  Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn
Journal:  Neuro Oncol       Date:  2016-02-09       Impact factor: 12.300

9.  Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.

Authors:  Stefanie Milker-Zabel; Angelika Zabel-du Bois; Marcus Henze; Peter Huber; Daniela Schulz-Ertner; Angelika Hoess; Uwe Haberkorn; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-02-20       Impact factor: 7.038

Review 10.  EANO guidelines for the diagnosis and treatment of meningiomas.

Authors:  Roland Goldbrunner; Giuseppe Minniti; Matthias Preusser; Michael D Jenkinson; Kita Sallabanda; Emmanuel Houdart; Andreas von Deimling; Pantelis Stavrinou; Florence Lefranc; Morten Lund-Johansen; Elizabeth Cohen-Jonathan Moyal; Dieta Brandsma; Roger Henriksson; Riccardo Soffietti; Michael Weller
Journal:  Lancet Oncol       Date:  2016-08-30       Impact factor: 41.316

View more
  1 in total

1.  Theranostics in Oncology-Thriving, Now More than Ever.

Authors:  Rudolf A Werner; Takahiro Higuchi; Martin G Pomper; Steven P Rowe
Journal:  Diagnostics (Basel)       Date:  2021-04-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.